$Novo-Nordisk A/S(NVO)$ Novo Nordisk is deeply undervalued, trading at a forward P/E of 14, despite 20%+ top and bottom-line growth and dominant weight-loss market share.
The anti-obesity market is set to grow nearly 10x by 2035; Novo's 71% international share and strong R&D position it for outsized gains.
Current valuation reflects excessive pessimism—NVO is oversold, with profitability and growth far outpacing sector averages, making this a rare buying opportunity.
I rate Novo Nordisk a Strong Buy with a $110 price target in 12–18 months, supported by robust fundamentals and powerful industry tailwinds.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments
通过加入该小组，您将能够直接与我们的社区团队联系和享受特别红利哦~
📲如果您有兴趣，请联系我们电报：+60194009513（请提供您的老虎证券用户名+标语“老虎新星俱乐部”）。